

Spondyloarthritis Committee meeting

Date: 11th and 12th January 2016

Location: Bollin meeting room, NICE Manchester

Minutes: Final

Committee members present:		
	Day 1	Day 2
Gary McVeigh (Chair) (GM)	Present for all items	Present for all items
David Chandler (DCh)	Present for all items	Present for all items
Debbie Cook (DC)	Present for all items	Present for all items
Charlotte Davis (CD)	Present for all items	Present for all items
Nicola Goodson (NG)	Present for all items	Present for all items
Tina Hawkins (TH)	Present for all items	Present from item 2 to 4
Jon Packham (JP)	Present for all items	Present for all items
Carol McCrum (CM)	Present for all items	Present for all items
Louise Warburton (LW)	Present for all items	Present for all items

In attendance		
	Day 1	Day 2
Rachel Houten (RH) <i>Health Economist</i>	Present for all items	Present for all items
Katherine McAllister (KM) <i>Technical Analyst</i>	Present for all items, with the exception of item 1, and part of items 2&4	Present for all items
Ian Mather (IM) <i>Business Analyst</i>	Present to the end of item 3.	N/A
Vonda Murray (VM) <i>Project Manager</i>	Present for all items	Present for all items
Robby Richey (RR) <i>Technical Analyst</i>	Present for all items	Present for all items

SA GDG 11 minutes

Gabriel Rogers (GR) - <i>Technical Advisor (HE)</i>	Present for all items	Present for all items
Sue Spiers (SS) <i>Associate Director</i>	Present for all items	Present to item 4

Observers:		
	Day 1	Day 2
Bing Luan-Gallagher <i>Resource Impact Assessment Administrator</i>	Present to the end of item 3.	N/A

Apologies:	
Nicky Bassett-Burr	Co-opted expert
Sue Ellerby	Clinical Advisor
Amanda Isdale	Committee member
Caroline Keir	Commissioning Manager
Shelly Patel	Medicines Advisor
Winston Rennie	Co-opted expert

Day 1
1. Welcome, minutes of the last meeting, declarations of interest and objectives for the meeting
<p>The Chair welcomed the Committee members and attendees to day 1 of the eleventh guideline development group meeting. He provided a brief overview and objectives of the day highlighting the information that would be discussed. IM provided a brief introduction.</p> <p>The Chair informed the committee that additional development time had been allocated to the guideline, and an additional GDG meeting would be required. It was agreed that a list of the agreed meeting dates would be circulated.</p> <p>Action - VM to circulate the dates of scheduled meetings to the committee.</p> <p>Apologies were noted, as recorded above, and minutes of the last meeting were agreed as an accurate record.</p> <p>All Committee members were asked to share any new conflicts of interest which have not previously been declared. One new conflict of interest declared, and noted</p>

SA GDG 11 minutes

below.

Name	Declarations of Interest, date declared	Type of interest	Decision taken
Tina Hawkins	Is planning to apply for a Fellowship with National Institute for Health Research, on spondyloarthritis 12.01.16	Personal, non-financial, specific interest	Declare and participate

Having reviewed historical declaration of interests it was agreed that all committee members were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.

2. Health economics update; agree model parameter

RH & GR presented the economic model taking the group through the data used and structure to ensure the GDG were in agreement with the clinical assumptions made. The group discussed and provided input, particularly with regards to representing the diagnosis and treatment of spondyloarthritis in clinical practice.

3. Overview of resource impact assessment

IM explained the role of the team, the purpose of the tools they create and what is required of the committee.

The Chair thanked IM for the presentation and suggested perhaps the committee would find a copy of the presentation useful.

Action - VM to circulate presentation to the committee

4. Review question 3 - *What are the obstacles to a prompt diagnosis of spondyloarthritis?*

RR reminded the committee of the agreed review protocol for this question. In total 8 studies were included which included cross-sectional surveys and interview based studies.

The committee agreed that this question would be revisited at a later date taking into consideration the outcome of future review questions which would further support any recommendations in this area

5. TICOPA study

Review Question 23 - When a first-line treatment has failed, what is the effectiveness of the following for managing spondyloarthritis:

- Switching to a different pharmacological intervention?
- Augmenting with a second pharmacological intervention?

SA GDG 11 minutes

Recommendations have already been made for this question. The recent publication of the TICOPA study was identified by some of committee members as relevant evidence in this area.

RR summarised the review protocol, the evidence previously presented, and the current recommendation. RR provided a summary of the evidence and RH presented an overview of the health economic aspects of the paper.

The committee agreed that no change was necessary to the recommendations previously made.

6. Research recommendations

KM summarised the research recommendations made by the committee to date, and invited the GDG to identify any further research recommendations.

It was agreed that a representative of the National Institute for Health Research will be invited to attend a later meeting to support the committee with prioritisation and formulation of research recommendations.

6. Summary and next steps

There were no additional matters arising. The Chair briefly summarised the discussions from the meeting before closing day 1.

Day 2

1. Welcome, declarations of interest and objectives for the meeting

The Chair welcomed the Committee members to day 2 of the eleventh guideline development group meeting. The Chair went through the revised agenda for day 2, giving a brief overview of what would be discussed.

Apologies were noted, as recorded above

No new conflicts of interest were declared and it was agreed that all committee members were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.

The Chair highlighted that GDG 12 or GDG 13 will be altered to a 1 day meeting. The GDG meeting in August (post consultation), will change to November 2016. There will be an additional meeting in May or June. Confirmation of this information will be provided by the end of the week to the committee.

2. (Day 1 agenda item) Health economics update; agree model parameter

RH & GR presented information on the proposed parameters and structure of the economic model. The group discussed and shared their clinical experience and

SA GDG 11 minutes

knowledge in order to inform the model.
2. Review question 31 update: multidisciplinary teams
RR reminded the committee of the agreed review protocol. No eligible studies were identified for inclusion and using their clinical experience and expertise the committee updated the recommendations in this area.
3. Review question 7 - What is the diagnostic utility of a HLA B27 test for investigating suspected spondyloarthritis? Review question 8 - What is the diagnostic utility of an erythrocyte sedimentation rate test for investigating suspected spondyloarthritis? Review question - What is the diagnostic utility of a C-reactive protein test for investigating suspected spondyloarthritis?
KM reminded the committee of the agreed review protocol and presented the evidence from the included studies. Based on the evidence presented and their own clinical experience and expertise the committee made 1 recommendation for RQ 7, and 1 recommendation made for RQs 8 and 9
4. Review question 5 - What is the effectiveness of information gathering (for example family history, self-report questionnaires, and screening criteria) in improving early diagnosis of spondyloarthritis?
KM reminded the committee of the agreed review protocol. No studies met the inclusion criteria and therefore the committee made consensus recommendations based on their clinical experience and expertise.
5. Review Questions 1&2 queries
The committee were asked to consider how to approach older studies in the evidence base which may represent axial disease differently to newer studies. It was agreed to include all relevant studies but note the quality concerns when considering and making recommendations.
7. Summary and next steps
The Chair thanked the committee for their work. The Chair reminded committee members who require accommodation to be arranged by NICE to make this request at least two weeks before the meeting

Date of next meeting: TBC